effect profiles. The company is harnessing the untapped potential of a synthetic active pharmaceutical ingredient known as cannabidiol, which is currently being studied for the treatment of epilepsy, pain, arthritis, and schizophrenia, amongst other indications. Botanix is preparing for human trials utilizing synthetic cannabidiol in a proprietary drug delivery system (PermetrexTM) for direct skin delivery of the therapy.